More on SYRE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-406.7% Growth)
- Ratings (9.3 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Spyre Therapeutics (NQ:SYRE)
Delayed: 87.50 +0.57 (0.66%)
Prev. Close $86.93  
Open$85.56 
52 Wk High$ 
52 Wk Low$ 
Day High$88.24 
Day Low$85.26 
P/E N/A  
EPS$ 
Volume363,332 

Friends, Peers and Foes (?): ABVX, ORKA, INTU, NCNO, SMTC (more...)

Sep 9, 2026 05:40 AM Baird Reiterates Outperform Rating on Spyre (SYRE)
Sep 8, 2026 08:04 AM Spyre's SPY003 meets primary endpoint in Phase 2 UC trial
Sep 8, 2026 08:00 AM Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Sep 3, 2026 04:05 PM Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Aug 27, 2026 06:19 AM Spyre (SYRE) PT Lowered to $116 at Baird
Aug 27, 2026 02:20 AM Guggenheim Reiterates Buy Rating on Spyre (SYRE)
Aug 26, 2026 07:28 AM Spyre (SYRE) Reiterated at Buy by Stifel on Topline Results From RA PoC Sub-Study
Aug 25, 2026 04:41 PM After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO
Aug 25, 2026 04:05 PM Form 8-K Spyre Therapeutics, Inc. For: Aug 25
Aug 25, 2026 04:01 PM Spyre RA drug trial misses internal bar despite some efficacy
View All Articles

Entities mentioned with SYRE

View All Entities